US EditionNovo Nordisk's Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study
In the STEER study, Wegovy reduced major cardiovascular events by 57% compared to tirzepatide in US adults with obesity and cardiovascular disease without diabetes, Novo Nordisk reported.
- Novo Nordisk said its weight-loss drug Wegovy reduced the risk of heart attack, stroke or death by 57% compared to Eli Lilly's rival medicines Mounjaro and Zepbound in overweight and obese patients with cardiovascular disease but not diabetes.
- The study showed a 29% reduction in heart risk and death from any cause in Wegovy users compared with tirzepatide users, regardless of treatment gaps.
- The findings could provide a boost for Novo, which has been losing U.S. market share to Zepbound since becoming Europe's most valuable company last year on booming sales of Wegovy.
23 Articles
23 Articles
Is Novo Nordisk Stock a Buy Now? @themotleyfool #stocks $NVO $LLY
Key PointsNovo Nordisk announced a 57% reduction in the risk of heart attacks, strokes, and death by any cause for patients taking Wegovy versus Eli Lilly's Zepbound.The Steer study results aren't nearly as exciting as they might appear.The Steer study's implications are limited, but that doesn't mean there isn't a bright future for Wegovy and Novo Nordisk.10 stocks we like better than Novo Nordisk › Danish pharmaceutical giant Novo Nordisk (NYS…
Novo Shares Gain As Wegovy Shows Big Edge Over Lilly's Tirzepatide In Heart Study
Novo Shares Gain As Wegovy Shows Big Edge Over Lilly's Tirzepatide In Heart Study Novo Nordisk shares rose in Copenhagen trading on Monday after the pharmaceutical giant reported on Sunday that its weight-loss drug Wegovy reduced the risk of heart attack, stroke, or death by 57% compared with tirzepatide, the active ingredient in Eli Lilly's Mounjaro and Zepbound. The new findings come from a STEER real-world study, which collected evidence fr…
Wegovy cuts heart risk by 57% vs. Lilly in weight-loss study | Honolulu Star-Advertiser
Novo Nordisk said on Sunday its blockbuster weight-loss drug Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly’s rival medicines Mounjaro and Zepbound in a real-world comparison of overweight and obese patients with cardiovascular disease but not diabetes.
Novo Nordisk's Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease
Compared with tirzepatide, Wegovy® (semaglutide) 2.4 mg showed a significant 57% greater reduction in the risk of heart attack, stroke or death from any cause, in people with overweight or obesity and cardiovascular disease (CVD) while on treatment1Similarly, the study…
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
